“The kinds of biotechs best for investors who aren’t huge risk-takers are those that generate solid revenue growth, are profitable (or soon will be), and have promising pipelines,” advises the author of today’s article, who proceeds to highlight three stocks that appear to match this profile to consider buying this month. For more, CLICK HERE.